Using LDL to Deliver Cancer Drugs
Author Information
Author(s): S. Vitols, K. Soderberg-Reid, M. Masquelier, B. Sjöström, C. Peterson
Primary Institution: Karolinska Hospital
Hypothesis
Can low density lipoprotein (LDL) be used as a carrier for anti-cancer agents to improve their effectiveness?
Conclusion
The study found that the WB 4291-LDL complex significantly prolonged survival in mice with leukemia.
Supporting Evidence
- The WB 4291-LDL complex contained about 1,500 drug molecules per LDL particle.
- Median survival time for treated mice with i.p. leukemia was 40 days compared to 17 days for controls.
- 40% of treated mice became long-term survivors after i.p. administration.
Takeaway
Researchers found a way to use a type of fat in the body called LDL to help deliver cancer-fighting drugs directly to cancer cells, making them more effective.
Methodology
The study involved incorporating a water-insoluble drug into LDL and testing its effects on cultured cells and mice with leukemia.
Limitations
The study did not compare the therapeutic effects of the drug in free form versus as an LDL complex.
Participant Demographics
Male Balb-C mice and male white New Zealand rabbits were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website